BR0309570A - Fatores camp quiméricos para vacinação contra infecção por streptococcus - Google Patents

Fatores camp quiméricos para vacinação contra infecção por streptococcus

Info

Publication number
BR0309570A
BR0309570A BR0309570-3A BR0309570A BR0309570A BR 0309570 A BR0309570 A BR 0309570A BR 0309570 A BR0309570 A BR 0309570A BR 0309570 A BR0309570 A BR 0309570A
Authority
BR
Brazil
Prior art keywords
camp
streptococcus infection
factors
chimeric
camp factors
Prior art date
Application number
BR0309570-3A
Other languages
English (en)
Other versions
BRPI0309570B1 (pt
Inventor
Andrew A Potter
Jose Perez-Casal
Michael Fontaine
Ximming Song
Original Assignee
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saskatchewan filed Critical Univ Saskatchewan
Publication of BR0309570A publication Critical patent/BR0309570A/pt
Publication of BRPI0309570B1 publication Critical patent/BRPI0309570B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"FATORES CAMP QUIMéRICOS PARA VACINAçãO CONTRA INFECçãO POR STREPTOCOCCUS". é descrito o gene do fator CAMP de Streptococcus uberis (S. uberis) , assim como a produção de fator CAMP recombinante a partir dele. Além disso, são reveladas construções quiméricas de fator CAMP, que incluem epitopos de fator CAMP de mais de uma espécie bacteriana. Os fatores CAMP e quimeras que incluem o mesmo podem ser usados em composições imunogênicas para a prevençao e tratamento de infecções bacterianas.
BRPI0309570A 2002-04-26 2003-04-24 fatores camp quiméricos para vacinação contra infecção por streptococcus BRPI0309570B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/134,021 US6936259B2 (en) 1995-06-08 2002-04-26 CAMP factor of Streptococcus uberis
PCT/CA2003/000587 WO2003091437A1 (en) 2002-04-26 2003-04-24 Chimeric camp factors for vaccination against streptococcus infection

Publications (2)

Publication Number Publication Date
BR0309570A true BR0309570A (pt) 2005-02-22
BRPI0309570B1 BRPI0309570B1 (pt) 2016-12-27

Family

ID=29268791

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0309570A BRPI0309570B1 (pt) 2002-04-26 2003-04-24 fatores camp quiméricos para vacinação contra infecção por streptococcus

Country Status (10)

Country Link
US (2) US6936259B2 (pt)
EP (1) EP1499726A1 (pt)
JP (1) JP2005523704A (pt)
AR (1) AR039460A1 (pt)
AU (1) AU2003229416B2 (pt)
BR (1) BRPI0309570B1 (pt)
CA (1) CA2483564A1 (pt)
MX (1) MXPA04010646A (pt)
NZ (2) NZ536232A (pt)
WO (1) WO2003091437A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833134B2 (en) * 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
EP2277894A1 (en) * 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
WO2004018646A2 (en) * 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
ES2505695T3 (es) * 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
WO2005059165A2 (en) * 2003-12-09 2005-06-30 Biomerieux, Inc. Methods for detecting bacterial pathogens
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2007010256A1 (en) * 2005-07-19 2007-01-25 Badrilla Limited Agents for and method of quantifying multiple related components in a biological system
AU2007229275B2 (en) 2006-03-23 2013-02-07 Agriculture Victoria Services Pty Ltd Antimicrobial protein
PL2054431T3 (pl) * 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
US20110038879A1 (en) * 2006-10-30 2011-02-17 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
CN103694351A (zh) * 2007-06-05 2014-04-02 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
CN101969992B (zh) 2007-09-12 2014-10-01 诺华股份有限公司 Gas57突变型抗原和gas57抗体
CN104292312A (zh) 2007-12-21 2015-01-21 诺华股份有限公司 链球菌溶血素o的突变形式
EP2257569B1 (en) * 2008-03-13 2014-10-01 Agriculture Victoria Services PTY Limited Vectors for expression of antimicrobial peptides in mammary gland
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
KR101712705B1 (ko) * 2014-08-19 2017-03-07 경북대학교 산학협력단 스트렙토코커스 애갈락티에 검출용 조성물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
DK0626452T3 (da) 1993-05-17 2000-02-14 Akzo Nobel Nv Vaccine mod infektion af Streptococcus suis
DE69635952T2 (de) 1995-06-08 2007-02-08 The University Of Saskatchewan Camp faktor aus streptococcus uberis

Also Published As

Publication number Publication date
US20040219639A1 (en) 2004-11-04
AU2003229416B2 (en) 2008-05-01
MXPA04010646A (es) 2005-02-17
NZ549506A (en) 2008-08-29
CA2483564A1 (en) 2003-11-06
BRPI0309570B1 (pt) 2016-12-27
EP1499726A1 (en) 2005-01-26
US6936259B2 (en) 2005-08-30
JP2005523704A (ja) 2005-08-11
AR039460A1 (es) 2005-02-23
US7700117B2 (en) 2010-04-20
NZ536232A (en) 2006-12-22
US20030072765A1 (en) 2003-04-17
WO2003091437A1 (en) 2003-11-06
AU2003229416A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
NL300897I2 (nl) Neisseira meningitidis serogroep B recombinant gelipideerd fHbp subfamilie A05 eiwit
NO20061911L (no) Immunogene sammensetninger
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
MY138708A (en) Biaryloxymethylarenecarboxylic acids
HUP0102304A1 (hu) B Csoportba tartozó Streptococcus antigének
ATE522541T1 (de) Bakterielle adhäsine konformere
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
WO2008133208A1 (ja) ペプチド免疫応答増強方法
SI1675956T1 (sl) Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov
DE50206761D1 (de) Fluorhaltige copolymere, deren herstellung und verwendung
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
WO2021158755A3 (en) Leptospiral proteins and uses thereof
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 17 (DEZESSETE) DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)